Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pacira Pharmaceuticals (PCRX) PT Raised to $50 at RBC Capital
August 3, 2018 7:56 AM EDTRBC Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $50.00 (from $44.00) while maintaining a Outperform rating.
... MoreNeedham & Company Upgrades Pacira Pharmaceuticals (PCRX) to Buy; 'All Signs Point to a Significant Exparel Growth Inflection'
August 3, 2018 7:27 AM EDTNeedham & Company upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Hold to Buy with a price target of $54.00.
Analsyt Serge Belanger commented, " Exparel's strong 2Q18 performance ($80.4MM, +15%Yr/ Yr) appears to be accelerating with sales growth of 16%Yr/Yr in May and 18%Yr/Yr... More
Pacira Pharmaceuticals (PCRX) PT Raised to $53 at Seaport Global Securities
August 3, 2018 7:23 AM EDTSeaport Global Securities raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $53.00 (from $48.00) while maintaining a Buy rating.
... MorePacira Pharmaceuticals (PCRX) PT Raised to $40 at BMO Capital
August 3, 2018 6:57 AM EDTBMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $40.00 (from $34.00) while maintaining a Market Perform rating.
Analsyt Gary Nachman commented, "PCRX reported 2Q18 non-GAAP revenue of $81mmabove BMO/consensus $77mm/$76mm, and EPS of $0.24 above BMO/consensus $0.09/$0.07. Solid 2Q... More
Pacira Pharmaceuticals (PCRX) PT Raised to $50 at Barclays
August 3, 2018 5:09 AM EDTBarclays raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $50.00 (from $40.00) while maintaining a Overweight rating.
... More